Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies

The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk in the Chinese population has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hongjie, Yan, Yulan, Li, Taijie, Li, Ruolin, Li, Meng, Li, Shan, Qin, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932174/
https://www.ncbi.nlm.nih.gov/pubmed/24078451
http://dx.doi.org/10.1007/s13277-013-1234-9
_version_ 1782304757623291904
author Liang, Hongjie
Yan, Yulan
Li, Taijie
Li, Ruolin
Li, Meng
Li, Shan
Qin, Xue
author_facet Liang, Hongjie
Yan, Yulan
Li, Taijie
Li, Ruolin
Li, Meng
Li, Shan
Qin, Xue
author_sort Liang, Hongjie
collection PubMed
description The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk in the Chinese population has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible articles were identified through search of databases including Medline, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese), China National Knowledge Infrastructure (CNKI, Chinese), and Wangfang Database (Chinese). The association between the MTHFR polymorphism and breast cancer risk was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Finally, a total of 22 studies with 6,103 cases and 7,913 controls were included in our meta-analysis: 13 studies with 3,273 cases and 4,419 controls for C677T polymorphism and 9 studies with 2,830 cases and 3,494 controls for A1298C polymorphism. With regard to C677T polymorphism, significant association was found with breast cancer risk under three models (T vs. C: OR = 1.12, 95 % CI = 1.02–1.23, P = 0.015; TT vs. CC: OR = 1.35, 95 % CI = 1.10–1.67, P = 0.005; TT vs. CC/CT: OR = 1.37, 95 % CI = 1.11–1.70, P = 0.004). There was no significant association found between A1298C polymorphism and breast cancer risk under all genetic models (C vs. A: OR = 0.96, 95 % CI = 0.89–1.03, P = 0.268; CC vs. AA: OR = 0.98, 95 % CI = 0.77–1.26, P = 0.899; AC vs. AA: OR = 0.95, 95 % CI = 0.88–1.02, P = 0.174; CC vs. AC/AA: OR = 1.00, 95 % CI = 0.78–1.28, P = 0.996, CC/AC vs. AA: OR = 0.96, 95 % CI = 0.89–1.02, P = 0.196). In summary, during this meta-analysis, we found that MTHFR C677T polymorphism was significantly associated with breast cancer risk in the Chinese population. Meanwhile, MTHFR A1298C polymorphism was not associated with breast cancer risk in the Chinese population.
format Online
Article
Text
id pubmed-3932174
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-39321742014-02-28 Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies Liang, Hongjie Yan, Yulan Li, Taijie Li, Ruolin Li, Meng Li, Shan Qin, Xue Tumour Biol Research Article The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk in the Chinese population has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible articles were identified through search of databases including Medline, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese), China National Knowledge Infrastructure (CNKI, Chinese), and Wangfang Database (Chinese). The association between the MTHFR polymorphism and breast cancer risk was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Finally, a total of 22 studies with 6,103 cases and 7,913 controls were included in our meta-analysis: 13 studies with 3,273 cases and 4,419 controls for C677T polymorphism and 9 studies with 2,830 cases and 3,494 controls for A1298C polymorphism. With regard to C677T polymorphism, significant association was found with breast cancer risk under three models (T vs. C: OR = 1.12, 95 % CI = 1.02–1.23, P = 0.015; TT vs. CC: OR = 1.35, 95 % CI = 1.10–1.67, P = 0.005; TT vs. CC/CT: OR = 1.37, 95 % CI = 1.11–1.70, P = 0.004). There was no significant association found between A1298C polymorphism and breast cancer risk under all genetic models (C vs. A: OR = 0.96, 95 % CI = 0.89–1.03, P = 0.268; CC vs. AA: OR = 0.98, 95 % CI = 0.77–1.26, P = 0.899; AC vs. AA: OR = 0.95, 95 % CI = 0.88–1.02, P = 0.174; CC vs. AC/AA: OR = 1.00, 95 % CI = 0.78–1.28, P = 0.996, CC/AC vs. AA: OR = 0.96, 95 % CI = 0.89–1.02, P = 0.196). In summary, during this meta-analysis, we found that MTHFR C677T polymorphism was significantly associated with breast cancer risk in the Chinese population. Meanwhile, MTHFR A1298C polymorphism was not associated with breast cancer risk in the Chinese population. Springer Netherlands 2013-09-27 /pmc/articles/PMC3932174/ /pubmed/24078451 http://dx.doi.org/10.1007/s13277-013-1234-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Research Article
Liang, Hongjie
Yan, Yulan
Li, Taijie
Li, Ruolin
Li, Meng
Li, Shan
Qin, Xue
Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title_full Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title_fullStr Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title_full_unstemmed Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title_short Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case–control studies
title_sort methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in chinese population: a meta-analysis of 22 case–control studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932174/
https://www.ncbi.nlm.nih.gov/pubmed/24078451
http://dx.doi.org/10.1007/s13277-013-1234-9
work_keys_str_mv AT lianghongjie methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT yanyulan methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT litaijie methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT liruolin methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT limeng methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT lishan methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies
AT qinxue methylenetetrahydrofolatereductasepolymorphismsandbreastcancerriskinchinesepopulationametaanalysisof22casecontrolstudies